Harvoni

Merck comes up short in last-ditch effort to revive $2.54B patent verdict against Gilead
Merck comes up short in last-ditch effort to revive $2.54B patent verdict against Gilead
Fierce Pharma
Merck
Idenis
Gilead Sciences
patents
Harvoni
Sovaldi
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
China approves Descovy, Harvoni, Hemlibra
China approves Descovy, Harvoni, Hemlibra
BioCentury
China
Harvoni
Descovy
Hemlibra
Roche
Gilead Sciences
Flag link:
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
CP Wire
Gilead Sciences
generics
Epclusa
Harvoni
hepatitis C
Asegua Therapeutics
Flag link:
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
Gilead
Epclusa
Harvoni
Flag link:
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Biopharma Dive
Gilead Sciences
Merck
patents
Sovaldi
Harvoni
hepatitis C
Idenix
Flag link:
Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
Reuters
Gilead Sciences
hepatitis C
patents
Merck
Sovaldi
Harvoni
Flag link:
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Fierce Pharma
AbbVie
Mavyret
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
Motley Fool
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Epclusa
Flag link:
How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas
How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas
Fierce Pharma
drug launches
Keytruda
Harvoni
Opdivo
Merck
Bristol-Myers Squibb
Gilead Sciences
Flag link:
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
Forbes
drug pricing
hepatitis C
Martin Shkreli
Gilead Sciences
Harvoni
Sovaldi
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
Gilead works on lifecycle management for Sovaldi as Hep C franchise wanes
BioPharma Dive
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Gilead Hep C Drugs Get Supplemental FDA Nod
Gilead Hep C Drugs Get Supplemental FDA Nod
Investopedia
Gilead Sciences
hepatitis C
FDA
Harvoni
Sovaldi
Flag link:
Gilead's Harvoni ads go from before to after with new creative focused on hep C cure
Gilead's Harvoni ads go from before to after with new creative focused on hep C cure
Fierce Pharma
Gilead Sciences
Harvoni
drug ads
DTC ads
hepatitis C
Flag link:
Gilead pushes hep C testing in baby boomers as its blockbusters plummet
Gilead pushes hep C testing in baby boomers as its blockbusters plummet
Fierce Pharma
Gilead Sciences
hepatitis C
baby boomers
DTC advertising
Harvoni
Sovaldi
Flag link:
Gilead cured hepatitis C. That’s become its biggest problem
Gilead cured hepatitis C. That’s become its biggest problem
Marketwatch
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns
Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns
Bloomberg
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:
Has Gilead Sciences' Cash Cow Finally Hit Bottom?
Has Gilead Sciences' Cash Cow Finally Hit Bottom?
Motley Fool
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Flag link:

Pages